Originally Aired: May 22, 2023
Time: 8:00 am PT, 11:00 am ET, 17:00 CET
In this proof-of-concept study, we established a novel liquid biopsy approach, MinimuMM-seq, enabling the enumeration and sequencing of CTCs to replace standard molecular cytogenetics performed on bone marrow of multiple myeloma patients.
CTCs harbored the same pathognomonic DNA abnormalities as clinical bone marrow samples. Longitudinal sampling of CTCs was able to track clonal dynamics over time.
These results demonstrate that genomic biomarker profiling of CTCs could be used clinically for screening and monitoring of patients with multiple myeloma in a minimally invasive manner.
A live Q&A session followed the presentation, offering a chance to pose questions to our expert panelist.
Postdoctoral Fellow
Dana-Farber Cancer Institute
Harvard Medicine School
Broad Institute
Produced with support from:
